ORIC Pharmaceuticals recently drew investor attention with positive analyst commentary, new clinical data on its lead oncology candidates, and a high-profile presentation at the 44th Annual J.P.

Investing.com - H.C. Wainwright has reiterated its Buy rating and $23.00 price target on ORIC Pharmaceuticals (NASDAQ:ORIC) ahead of what it describes as a "catalyst rich year" for the company in 2026 ...

Announced rinzimetostat (ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in ...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address ...

Investing.com - Piper Sandler initiated coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with an Overweight rating and a $22.00 price target on Wednesday, representing a potential 170% upside from the ...

ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) is one of the stocks that will double in 2026. On December 8, Wells Fargo raised the firm’s price target on Oric Pharmaceuticals to $25 from $19 and maintained ...

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

If you’re looking to add a printer to your home office or business space, odds are you’re considering one of two printer types, a laser versus an inkjet printer. The former, like the affordable ...

ORIC’s clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) ...

Oric Pharmaceuticals’ previously announced plan to focus resources on its two most advanced oncology drugs comes with a sting in its tail—the therapeutic-resistance-focused biotech is laying off 20% ...